Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Wisconsin Business Press.
Press releases published on October 18, 2025
Astra Bitcoin: Dr. Antoun Toubia Launches a Revolutionary Asset-Backed Ecosystem Built on Ethereum
TBILISI, Georgia, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Astra Bitcoin officially debuts as a new force in digital finance — a blockchain ecosystem where real-world assets meet decentralized innovation. Founded by Dr. Antoun Toubia, a renowned figure in wealth …
NUTX 3-DAY DEADLINE ALERT: Nutex Health (NUTX) Faces Investor Lawsuit Over Alleged Revenue Inflation Scheme-- Hagens Berman
SAN FRANCISCO, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Nutex Health Inc. (NASDAQ: NUTX), a publicly traded operator of micro-hospitals and healthcare facilities, is under legal scrutiny following a class-action lawsuit that accuses the company of orchestrating a …
Cearvol präsentiert auf der EUHA 2025 sein komplettes Hörgeräte-Sortiment und stellt sein Flaggschiff Wave mit fortschrittlicher KI- und Touchscreen-Technologie vor
NÜRNBERG, Deutschland, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Cearvol, ein führender Innovator in der Akustikbranche, wird auf der EUHA 2025 sein komplettes Sortiment an Hörgeräten der nächsten Generation vorstellen, darunter seine intelligenten Aquarius …
VRA Investor News: If You Have Suffered Losses in Vera Bradley, Inc. (NASDAQ: VRA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Vera Bradley, Inc. (NASDAQ: VRA) resulting from allegations that Vera …
C3.ai, Inc. (AI) Hit With Securities Class Action After Shares Crash 25% On Large Revenue Miss -- Hagens Berman
SAN FRANCISCO, Oct. 18, 2025 (GLOBE NEWSWIRE) -- A new class action lawsuit is targeting enterprise AI software company C3.ai (NYSE: AI) and its senior leadership, alleging they misled investors about the company's financial health and growth prospects. …
FCX Investor News: If You Have Suffered Losses in Freeport-McMoRan Inc. (NYSE: FCX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Freeport-McMoRan Inc. (NYSE: FCX) resulting from allegations that …
DeFi crypto Mutuum Finance (MUTM) Onboards Over 17,300 Investors With 70% of Phase 6 Allocated
Dubai, UAE , Oct. 18, 2025 (GLOBE NEWSWIRE) -- The DeFi market continues to evolve rapidly, and new protocols are emerging that aim to push the industry forward in both utility and adoption. One project gaining major attention is Mutuum Finance (MUTM), a …
Reconstruction and Opportunities: The CDFG Consumer White Paper 2024-2025 is Released
Reconstruction and Opportunities: The CDFG Consumer White Paper 2024-2025 is Released Reconstruction and Opportunities: The CDFG Consumer White Paper 2024-2025 is Released Source: CDFG Consumer White Paper 2024-2025 Source: CDFG Consumer White Paper 2024- …
Newfoundland and Labrador Victims and Survivors of Alcohol and Drug-Related Crashes Remembered at MADD Canada’s Annual Memorial Monument Ceremony
GRAND-FALLS WINDSOR, Newfoundland and Labrador, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Today, families and community members will gather at MADD Canada’s annual Candlelight Vigil Service and Memorial Monument Ceremony to honour those who have been killed or …
La cérémonie annuelle de MADD Canada au monument commémoratif de Terre-Neuve-et-Labrador rend hommage aux victimes et survivants de collisions liées à l’alcool et aux drogues
GRAND-FALLS WINDSOR, Terre-Neuve-et-Labrador, 18 oct. 2025 (GLOBE NEWSWIRE) -- Aujourd’hui, afin de rendre hommage aux victimes qui ont été tuées ou blessées dans des collisions liées à l’alcool, au cannabis et/ou à d’autres drogues, les familles et les …
ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025
Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus across patient subgroups Berlin, Germany, October 18, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, …
Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer
Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated with gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and in 11.5% of patients treated with …
Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)
Median radiographic progression free survival (“rPFS”) was 9.1 months and the six-month rPFS rate was 67% No patients discontinued study treatment due to a treatment-related adverse event (“TRAE”) MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc …
Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress
FTI mechanism addresses innate and adaptive resistance pathways common to targeted oncology therapies Early clinical and preclinical data support darlifarnib’s potential to enhance clinical benefit of PI3Kα-, KRAS- and tyrosine kinase inhibitors 50% …
Blazpay’s Phase 2 of Crypto Presale Surges With Over $250,000 Raised as XRP and Bitcoin Consolidate
PANAMA CITY , Oct. 18, 2025 (GLOBE NEWSWIRE) -- The crypto market is buzzing this week as investors weigh the latest developments in Bitcoin, XRP, and emerging AI-powered projects. Bitcoin remains relatively stable, trading between $109,655 and $111,844 …
AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer
Results from the TheraPb Phase 1b dose escalation presented at ESMO 2025 show a promising therapeutic index for 212Pb-ADVC001 in patients with metastatic castration-resistant prostate cancer (mCRPC) No dose-limiting toxicities and no treatment-related …
Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025
Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroups Median PFS was 15.5 months in the 120 mg palazestrant cohort across all patients In the 120 mg palazestrant cohort among patients with prior …